DiaMedica Therapeutics Inc.
DMAC
$3.53
-$0.01-0.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.62M | 7.85M | 7.83M | 8.32M | 8.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.68M | 24.11M | 22.38M | 21.49M | 21.27M |
| Operating Income | -26.68M | -24.11M | -22.38M | -21.49M | -21.27M |
| Income Before Tax | -24.41M | -21.66M | -19.86M | -19.22M | -19.34M |
| Income Tax Expenses | 30.00K | 43.00K | 43.00K | 43.00K | 43.00K |
| Earnings from Continuing Operations | -24.44 | -21.71 | -19.90 | -19.26 | -19.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.44M | -21.71M | -19.90M | -19.26M | -19.38M |
| EBIT | -26.68M | -24.11M | -22.38M | -21.49M | -21.27M |
| EBITDA | -26.64M | -24.07M | -22.35M | -21.46M | -21.24M |
| EPS Basic | -0.60 | -0.55 | -0.52 | -0.55 | -0.62 |
| Normalized Basic EPS | -0.38 | -0.34 | -0.33 | -0.35 | -0.38 |
| EPS Diluted | -0.60 | -0.55 | -0.52 | -0.55 | -0.62 |
| Normalized Diluted EPS | -0.38 | -0.34 | -0.33 | -0.35 | -0.38 |
| Average Basic Shares Outstanding | 161.58M | 156.79M | 151.99M | 141.23M | 129.72M |
| Average Diluted Shares Outstanding | 161.58M | 156.79M | 151.99M | 141.23M | 129.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |